INNOVATE (VATE) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Q2 2024 consolidated revenue was $313.1 million, down 15.1% year-over-year, mainly due to lower Infrastructure activity, partially offset by strong growth in Life Sciences and Spectrum.
Net income attributable to shareholders was $14.4 million, reversing a net loss in the prior year, reflecting improved operating results and a tax benefit.
Adjusted EBITDA rose to $26.7 million, up from $16.5 million year-over-year, driven by higher margins in Infrastructure and improved Spectrum performance.
All segments contributed to Adjusted EBITDA growth except Life Sciences, which saw higher losses due to MediBeacon.
DBM Global redeemed $41.8 million in Series A Preferred Stock, remitting cash to the parent, and a 1-for-10 reverse stock split was approved for August 2024.
Financial highlights
Q2 2024 revenue was $313.1 million, down from $368.8 million in Q2 2023; six-month revenue was $628.3 million, down 8.5% year-over-year.
Net income for Q2 2024 was $14.4 million ($0.10 per diluted share), compared to a net loss of $10.5 million in Q2 2023.
Adjusted EBITDA increased to $26.7 million from $16.5 million year-over-year.
Infrastructure revenue was $305.2 million (down 15.8% year-over-year), with Adjusted EBITDA of $32.5 million and gross margin expansion to 20.2%.
Life Sciences revenue grew 142.9% to $1.7 million, driven by R2's Glacial fx system sales; Spectrum revenue increased to $6.2 million, with Adjusted EBITDA nearly doubling to $1.5 million.
Outlook and guidance
Full-year results are expected to be slightly lower than last year, but margins are anticipated to be slightly better.
DBM Global maintains a robust pipeline for 2025, with backlog expected to stabilize around current levels.
Management expects to meet liquidity needs for at least the next twelve months but may require asset sales, refinancing, or capital raises for future compliance.
Broadcasting is focused on expanding ATSC 3.0 and 5G broadcast TV opportunities and leveraging new FCC incentives.
R2 Technologies expects continued growth in North America, with record system sales for the third consecutive quarter.
Latest events from INNOVATE
- Q4 2025 revenue up 61.7% to $382.7M, with strong Infrastructure growth and narrowing net loss.VATE
Q4 202526 Mar 2026 - Q3 revenue dropped 35.5% to $242.2M; growth in Life Sciences and Spectrum, but going concern risk remains.VATE
Q3 202416 Jan 2026 - Revenue declined, but Life Sciences and Spectrum grew; debt reduced and backlog remains strong.VATE
Q4 202425 Dec 2025 - Annual meeting to vote on directors, executive pay, auditor, and governance after major 2024 changes.VATE
Proxy Filing2 Dec 2025 - Director elections, say-on-pay, and auditor ratification up for vote at June 2025 meeting.VATE
Proxy Filing2 Dec 2025 - Annual meeting adjourned for technical reasons; voting postponed to June 18, 2024.VATE
Proxy Filing2 Dec 2025 - Revenue fell 22.7% to $242M, net loss $22M, Life Sciences grew, major debt refinancing completed.VATE
Q2 202523 Nov 2025 - Revenue dropped 13% to $274.2M; backlog and regulatory wins offset high debt risk.VATE
Q1 202515 Nov 2025 - Q3 revenue up 43% to $347.1M, net loss narrowed, and refinancing triggered asset sales.VATE
Q3 202513 Nov 2025